DL

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Retrieved on: 
Mardi, septembre 19, 2023
PK, DNA, NTCP, International, Assembly, DL, Biotechnology, HDV, CAM, Nm, Viral, Hepatitis B, Hepatitis B virus, Doctor of Philosophy, Liver cancer, Plasma, Patient, Liver, Poster, Viral hepatitis, HBV, Mutation, Vaccine

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis B virus (HBV) and hepatitis D virus (HDV) pipeline programs at the 2023 International HBV Meeting taking place in Kobe, Japan, September 19-23, 2023.

Key Points: 
  • At the meeting, one oral presentation will highlight progress in the company’s HBV/HDV oral entry inhibitor program including activity, selectivity and pharmacokinetic (PK) data that support advancement towards development candidate nomination.
  • A second oral presentation reports new data for ABI-4334 (4334), Assembly Bio’s most potent capsid assembly modulator (CAM) with a potential best-in-class profile, describing the prevention of HBV DNA integration in vitro.
  • The poster presentation, from the company’s interferon-α receptor (IFNAR) agonist program, characterizes small molecule IFNAR agonists that closely mimic interferon-α’s signaling.
  • In patients with chronic HBV infection, HBV DNA integration has been linked to the development of liver cancer.

AI-Supported Automated Code Remediation at Scale Is Catalyst for Mila, Moderne Partnership

Retrieved on: 
Lundi, septembre 18, 2023
Security, Data Management, Technology, Artificial Intelligence, Software, LLM, Maintenance, Hallucination, Human, Quebec, Partnership, DL, Multimedia, Research, Organization, Artificial intelligence, AI, Medical device, Moderne

Mila - Quebec AI Institute , the world’s largest academic deep learning (DL) research center, has established a partnership with Moderne , the pioneer in next-generation automated code remediation and analysis.

Key Points: 
  • Mila - Quebec AI Institute , the world’s largest academic deep learning (DL) research center, has established a partnership with Moderne , the pioneer in next-generation automated code remediation and analysis.
  • Moderne’s platform was built to specifically solve the problem of automated code remediation at scale.
  • The ML4Code reading group explores and discusses the newest papers related to coding tasks, such as code generation, code maintenance, and code translation.
  • These tasks are generally tackled using large language models (LLMs), such as StarCoder and Code LLama, and graph representations of code.

Eye Care Organizations Unite to Save Sight of Premature Infants Using Artificial Intelligence

Retrieved on: 
Jeudi, septembre 21, 2023
Retina, Telehealth, Partnership, National Eye, Life, DL, Oregon Health & Science University, Oxygen, Ophthalmology, Research, Paratriathlon, Eye, Patient, Premature, Orbis International, Risk, Child, SUNY Downstate Health Sciences University, ROP, Artificial intelligence, Diagnosis, National Eye Institute, FDA, National Institute for Health and Care Excellence, Disease, Pharmaceutical industry, Nursing, Birth control, Medical device, Orbis, AI

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Eye care nonprofit Orbis International is excited to announce a new strategic partnership with Siloam Vision to use the company's cloud-based telemedicine platform to expand access to eye care and prevent blindness in premature infants living in hard-to-reach communities. Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.

Key Points: 
  • Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.
  • Orbis and Siloam Vision have aligned missions to make sure no child starts out life blind from an avoidable cause.
  • We are excited to partner with Orbis to help save the sight of more preterm babies in hard-to-reach-communities."
  • Orbis is working to ensure eye care professionals everywhere can access these tools for free.

DL Holdings Announces Acquisition of Remaining 55% Stake in Family Office

Retrieved on: 
Vendredi, septembre 15, 2023
Communication, DL Holdings, DL, Research, Acquisition, Family, Property management

HONG KONG, Sept. 14, 2023 /PRNewswire/ -- DL Holdings Group Limited ("DL Holdings" or the "Company"; Stock Code: 1709.HK) has unveiled its acquisition of the remaining 55% stake in DL Family Office (HK) Limited ("DL Family Office") for HK$220 million.

Key Points: 
  • HONG KONG, Sept. 14, 2023 /PRNewswire/ -- DL Holdings Group Limited ("DL Holdings" or the "Company"; Stock Code: 1709.HK) has unveiled its acquisition of the remaining 55% stake in DL Family Office (HK) Limited ("DL Family Office") for HK$220 million.
  • This strategic move follows the successful acquisition of a 45% stake earlier this year, establishing DL Family Office as a wholly-owned subsidiary of DL Holdings.
  • Consequently, DL Holdings has emerged as the foremost asset management and financial services platform in Hong Kong, with a primary focus on multi-family office services.
  • In August, DL Holdings announced its investment in and acquisition of a new integrated commercial tower in Central, subsequently named "DL Tower."

AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Bre

Retrieved on: 
Lundi, septembre 11, 2023
CKM, TNBC, Roswell Park Comprehensive Cancer Center, Science of team science, AIM, IV, Senior, DL, Safety, DLT, SITC, Paclitaxel, Immunotherapy, Celecoxib, Cyclophosphamide, Trae tha Truth, Roswell Park, Research, AC, Neoplasm, Biomarker, Doctor of Philosophy, PCR, Assistant, NAC, Patient, Blood, Rintatolimod, Society for Immunotherapy of Cancer, Financial toxicity, Immunology, Infrared spectroscopy correlation table, Physician, NYSE, Medical imaging, Pharmaceutical industry, MD

OCALA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen® (rintatolimod) as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer (TNBC). The complete topline results are now available on ClinicalTrials.gov: NCT04081389.

Key Points: 
  • The complete topline results are now available on ClinicalTrials.gov: NCT04081389 .
  • “We are pleased to bolster our growing body of data from Ampligen and the results demonstrated in the Phase 1 study with the completed topline data report now in hand.
  • Secondary endpoints included pCR rate where 5/9 (56%) of patients attained pCR and 1 more patient attained ypTmic.
  • For more information about the Phase 1 study, visit ClinicalTrials.gov: NCT04081389 .

Subtle Medical Awarded $2.3M SBIR Grant to Expand Innovation in AI-powered Synthetic Imaging

Retrieved on: 
Mercredi, septembre 13, 2023
Acceleration, Medicine, Radiation, Magnetic resonance, DL, SBIR, Anatomy, Deep learning, Organizational founder, Spine, Intelligence, Research, Doctor of Philosophy, Bangladesh Technical Education Board, National Institutes of Health, Radiology, MRI, Motion, Acquisition, STIR, JACR, Ecosystem, RSNA, FDA, Health, Magnetic resonance imaging, Artifact, NIH, Software, Medical imaging, Medical device

MENLO PARK, Calif., Sept. 13, 2023 /PRNewswire/ -- Subtle Medical was awarded a federal SBIR grant from the National Institutes of Health (NIH) to expand their artificial intelligence (AI)-powered software solution, SubtleSYNTH™, which uses deep learning (DL) to synthesize Magnetic Resonance Imaging (MRI) contrasts from already-acquired contrasts. The software is currently FDA-pending for use in the spine, and the recently awarded grant will allow for further expansion to improve brain imaging with entire exam data. By using more data to enable even better quality and faster images, Subtle's suite of imaging solutions will redefine what's possible for the speed and quality of MRI imaging.

Key Points: 
  • The software is currently FDA-pending for use in the spine, and the recently awarded grant will allow for further expansion to improve brain imaging with entire exam data.
  • By using more data to enable even better quality and faster images, Subtle's suite of imaging solutions will redefine what's possible for the speed and quality of MRI imaging.
  • This is the third NIH SBIR grant Subtle Medical has been awarded.
  • Subtle continues to expand product lines in an effort to build a comprehensive ecosystem of solutions that support all imaging needs, from accelerated and low dose imaging, to tackling complex workflow solutions.

CARBONCO to Join Jeju Island Green Methanol Production Project

Retrieved on: 
Mardi, septembre 5, 2023
Green Technology, Alternative Energy, Energy, Environment, Utilities, Carbon, KRX, Maintenance, ThyssenKrupp, CFI, Partnership, Methanol, Electrolysis, Hydrogen, DL, Oxygen, Multimedia, Wind, Jeju Island, Ammonia, Water, Engineering, Film industry, Coal

CARBONCO , a company specializing in decarbonization solutions established by DL E&C Co., Ltd (DL ENGINEERING & CONSTRUCTION) (KRX: 375500), will engage in the Jeju Island Green Methanol Production Project.

Key Points: 
  • CARBONCO , a company specializing in decarbonization solutions established by DL E&C Co., Ltd (DL ENGINEERING & CONSTRUCTION) (KRX: 375500), will engage in the Jeju Island Green Methanol Production Project.
  • View the full release here: https://www.businesswire.com/news/home/20230904403533/en/
    CARBONCO, Jeju Energy Corporation, Gaoncell, and ThyssenKrupp have signed an agreement to produce e-methanol for the Jeju Island Green Methanol Production Project.
  • In particular, this project is catching attention as Korea's first Power to X (P2X) project driven by public-private collaboration.
  • ThyssenKrupp will offer the primary facilities for green hydrogen generation as well as technology and facilities as the original technology licensor for the e-methanol production process.

Deep Instinct Study Finds Significant Increase in Cybersecurity Attacks Fueled by Generative AI

Retrieved on: 
Mercredi, août 23, 2023
Technology, Online Privacy, Other Professional Services, Business, Finance, Apps, Applications, Professional Services, Artificial Intelligence, Other Technology, Software, Networks, Data Analytics, Fintech, Data Management, Insurance, Pressure, Plague, Instinct, Health, DL, Secop, Policy, Research, Privacy, Human voice, Public sector, Organization, EDR, Diving, Media, Workload, AI, Transport, Deep Instinct, Morale, Ciso, Endpoint detection and response, Medical device, Cryptocurrency

The study highlights the impact of generative AI in the cybersecurity industry, analyzing the technology’s positive and negative effect on organizations’ security postures and preparedness.

Key Points: 
  • The study highlights the impact of generative AI in the cybersecurity industry, analyzing the technology’s positive and negative effect on organizations’ security postures and preparedness.
  • Unsurprisingly, 75% of security professionals witnessed an increase in attacks over the past 12 months, with an astonishing 85% attributing this rise to bad actors using generative AI.
  • However, senior security professionals also view generative AI as a disruptive cybersecurity threat, with nearly half (46%) of respondents believing generative AI will increase their organization’s vulnerability to attacks.
  • The top three generative AI threat issues include growing privacy concerns (39%); undetectable phishing attacks (37%); and an increase in the volume and velocity of attacks (33%).

SDX sets industry standard with the adoption of the Digital Token Identifier standard for all its services

Retrieved on: 
Lundi, août 21, 2023
Destination Earth (European Union), DTI Data, DTI, Workflow, DL, ISO, DLT, Risk management, Central Securities Depository of Iran, Digital security, ESMA, Digital, SIX, Cryptocurrency, SDX

The financial industry is increasingly adopting the DTI ISO standard, a unique identifier for digital ledgers, tokens, and cryptocurrencies.

Key Points: 
  • The financial industry is increasingly adopting the DTI ISO standard, a unique identifier for digital ledgers, tokens, and cryptocurrencies.
  • Regulators can utilize DTIs to watch digital asset trades, ensure compliance with anti-money laundering and counter-terrorism financing requirements, and monitor risks associated with global stablecoins and other digital assets.
  • SDX integrates digital asset trading, settlement, and custody on a single and secure infrastructure (stock exchange and Central Security Depository).
  • Alex Kech, Head of Digital Securities at SDX, states, "SDX uses DTIs to identify currently crypto currencies and soon digital securities on our platform.

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Jeudi, août 17, 2023
Synovial sarcoma, MAGEA4, Paul Ehrlich Institute, Prevalence, Half-life, CRS, DL, Cohort, Clinical trial, Lung cancer, BRAF, Uveal melanoma, CTA, Head, Bristol Myers Squibb, Research, Cohort study, PRAME, TCR, Development, State Administrative Expenses, Sarcoma, ATM, Protein, Cytokine release syndrome, Patient, PEI, Administration, Melanoma, Corr, Entrepreneurship, Uterine cancer, Toxic shock syndrome toxin-1, Ovarian cancer, ORR, Safety, Breast cancer, Nivolumab, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency

“Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.

Key Points: 
  • “Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.
  • As per the latest data cut-off of April 4, 2023, ACTengine® IMA203 TCR-T monotherapy Cohort A showed a 67% confirmed objective response rate (cORR) in an interim clinical update announced on May 2, 2023.
  • Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME-targeted TCR-T monotherapy towards registration-directed trials is planned for 4Q 2023.
  • TCER® IMA402 (PRAME) – Immatics submitted a clinical trial application (CTA2) to the Paul-Ehrlich-Institute (PEI) in April 2023.